• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Could Sanofi’s (ENXTPA:SAN) Expanded Infant Vaccine Approval Reinforce Its Vaccines-Led Investment Story?

    Simply Wall St·08/05/2026 11:30:13
    Listen to the news
    • In late July 2026, the European Commission approved Sanofi’s MenQuadfi meningococcal vaccine for use in EU infants from six weeks of age, extending coverage against serogroups A, C, W, and Y and aligning dosing with routine pediatric schedules.
    • This broadened indication gives Sanofi an earlier entry point into infant immunization programs, potentially deepening its vaccines footprint in a high‑need, high‑risk population.
    • Next, we’ll examine how gaining infant approval for MenQuadfi across the EU fits into Sanofi’s broader vaccines-led investment narrative.

    Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

    Sanofi Investment Narrative Recap

    To own Sanofi, you need to believe its vaccines and specialty medicines can offset earnings volatility from heavy R&D spending, impairments and pricing pressure. The MenQuadfi infant approval in the EU strengthens the vaccines story but does not materially change the near term focus on restoring earnings momentum after sizeable intangible impairments and lower net margins in the first half of 2026.

    The most relevant recent announcement alongside MenQuadfi is Sanofi’s half year 2026 results, which showed higher sales but sharply lower net income and over €1,031 million of intangible asset impairments. Against that backdrop, progress in vaccines helps support the investment case, but pipeline execution and returns on past investments remain central catalysts for sentiment around the stock.

    However, investors should also be aware that if pricing pressure in core vaccine markets worsens or persists beyond current expectations, then ...

    Read the full narrative on Sanofi (it's free!)

    Sanofi's narrative projects €53.2 billion revenue and €10.7 billion earnings by 2029.

    Uncover how Sanofi's forecasts yield a €96.70 fair value, a 30% upside to its current price.

    Exploring Other Perspectives

    ENXTPA:SAN 1-Year Stock Price Chart
    ENXTPA:SAN 1-Year Stock Price Chart

    Some of the lowest target analysts were already cautious, assuming revenue of about €51,800 million and earnings of €9,300 million by 2029, and they see MenQuadfi’s infant win as only one piece of a much bigger vaccines story that might or might not offset the risks they worry about in areas like high adult vaccine investment commitments.

    Explore 7 other fair value estimates on Sanofi - why the stock might be worth just €82.00!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Sanofi?

    Our top stock finds are flying under the radar-for now. Get in early:

    • Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
    • Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
    • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.